2021-04-29 16:00Financial Performance - Operating revenue surged to CNY 466,758,070.10, a remarkable increase of 11,483.21% year-on-year[5] - The company reported a net loss of ¥15,751,950.02, a decrease of 31.82% compared to the previous year, mainly due to the positive impact of increased main business revenue on net loss[14] - The net loss for Q1 2021 was ¥15,751,950.02, an improvement from a net loss of ¥23,102,574.29 in Q1 2020[23] - Total comprehensive income for Q1 2021 was negative CNY 12,774,383.15, an improvement from negative CNY 23,100,310.37 in Q1 2020[28] Assets and Liabilities - Total assets increased by 11.49% to CNY 7,523,166,742.99 compared to the end of the previous year[5] - The total current assets as of March 31, 2021, amounted to approximately ¥5.81 billion, an increase from ¥5.42 billion as of December 31, 2020, representing a growth of about 7%[17] - Total liabilities rose to ¥1,189,920,589.15 in Q1 2021, up from ¥677,219,551.36 in Q1 2020[21] Cash Flow - Net cash flow from operating activities improved to CNY -12,415,330.54 from CNY -45,362,104.77 year-on-year[5] - The company experienced a net cash inflow from investment activities of ¥8,094,413.75, a change from the previous year's cash outflow, primarily due to the redemption of structured deposits[15] - The net cash inflow from financing activities was ¥228,283,550.03, a significant increase from the previous year's cash outflow, mainly due to short-term borrowings and cash received from minority shareholders' investments[15] - The company generated CNY 363,358,068.51 in cash from sales of goods and services in Q1 2021, compared to CNY 131,995.40 in Q1 2020[29] Research and Development - Research and development expenses accounted for 57.80% of operating revenue, a decrease of 923.25 percentage points compared to the previous year[6] - Research and development expenses increased by ¥230,255,643.34, a growth of 582.44%, as the company continued to increase R&D investment to maintain future product technology and quality advantages[14] - The company has ongoing research and development efforts for new products and technologies, particularly in the vaccine sector[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,414[8] - The largest shareholder, HKSCC NOMINEES LIMITED, held 39.63% of the shares[8] Market Strategy - The company is focused on expanding its market presence and enhancing its product development strategies[5] - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its growth strategy[16] Inventory and Receivables - Accounts receivable increased by ¥178,137,933.25, a growth of 804.47%, mainly due to the increase in accounts receivable resulting from the company's main business revenue[13] - Inventory rose by ¥169,680,211.36, an increase of 99.51%, primarily due to the increase in raw materials and turnover materials for research and production during the reporting period[13]